HUE030737T2 - Modafinil for use in the treatment of cocaine addicts - Google Patents
Modafinil for use in the treatment of cocaine addicts Download PDFInfo
- Publication number
- HUE030737T2 HUE030737T2 HUE13715263A HUE13715263A HUE030737T2 HU E030737 T2 HUE030737 T2 HU E030737T2 HU E13715263 A HUE13715263 A HU E13715263A HU E13715263 A HUE13715263 A HU E13715263A HU E030737 T2 HUE030737 T2 HU E030737T2
- Authority
- HU
- Hungary
- Prior art keywords
- cocaine
- treatment
- modafinil
- composition
- dissolution
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 14
- 229960001165 modafinil Drugs 0.000 title claims description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 title description 28
- 229960003920 cocaine Drugs 0.000 title description 14
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims description 26
- 239000012530 fluid Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims 1
- 244000060011 Cocos nucifera Species 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 239000007903 gelatin capsule Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000022497 Cocaine-Related disease Diseases 0.000 description 6
- 201000006145 cocaine dependence Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 206010013663 drug dependence Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010012335 Dependence Diseases 0.000 description 4
- 230000036626 alertness Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1200581A FR2987267B1 (fr) | 2012-02-28 | 2012-02-28 | Application du modafinil dans le traitement de substitution des cacainomanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE030737T2 true HUE030737T2 (en) | 2017-05-29 |
Family
ID=48083447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13715263A HUE030737T2 (en) | 2012-02-28 | 2013-02-25 | Modafinil for use in the treatment of cocaine addicts |
Country Status (33)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途 |
| CN105055412B (zh) * | 2015-08-20 | 2018-06-19 | 四川大学 | Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| CZ306618B6 (cs) * | 2000-10-11 | 2017-04-05 | Cephalon, Inc. | Kompozice obsahující sloučeniny modafinylu |
| US20040006532A1 (en) | 2001-03-20 | 2004-01-08 | David Lawrence | Network access risk management |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US7093476B2 (en) | 2004-09-15 | 2006-08-22 | Ut-Battelle, Llc | Method for fabricating thin californium-containing radioactive source wires |
| AU2006272874B2 (en) * | 2005-07-21 | 2010-03-11 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| AU2007272501A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Pharma International Limited | Nanoparticulate formulations of modafinil |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
-
2012
- 2012-02-28 FR FR1200581A patent/FR2987267B1/fr not_active Expired - Fee Related
-
2013
- 2013-02-25 DK DK13715263.3T patent/DK2819655T3/en active
- 2013-02-25 US US14/381,896 patent/US20150073055A1/en not_active Abandoned
- 2013-02-25 JP JP2014559270A patent/JP6163169B2/ja not_active Expired - Fee Related
- 2013-02-25 EP EP13715263.3A patent/EP2819655B1/fr active Active
- 2013-02-25 SI SI201330319A patent/SI2819655T1/sl unknown
- 2013-02-25 RS RS20160882A patent/RS55238B1/sr unknown
- 2013-02-25 NZ NZ628009A patent/NZ628009A/en not_active IP Right Cessation
- 2013-02-25 BR BR112014020626A patent/BR112014020626A2/pt not_active Application Discontinuation
- 2013-02-25 WO PCT/FR2013/000052 patent/WO2013128088A1/fr not_active Ceased
- 2013-02-25 KR KR1020147023180A patent/KR101897855B1/ko not_active Expired - Fee Related
- 2013-02-25 IN IN7831DEN2014 patent/IN2014DN07831A/en unknown
- 2013-02-25 LT LTEP13715263.3T patent/LT2819655T/lt unknown
- 2013-02-25 HU HUE13715263A patent/HUE030737T2/en unknown
- 2013-02-25 PT PT137152633T patent/PT2819655T/pt unknown
- 2013-02-25 AU AU2013224831A patent/AU2013224831B2/en not_active Ceased
- 2013-02-25 CA CA2863159A patent/CA2863159C/fr not_active Expired - Fee Related
- 2013-02-25 ES ES13715263.3T patent/ES2593276T3/es active Active
- 2013-02-25 CN CN201380011342.7A patent/CN104159575B/zh not_active Expired - Fee Related
- 2013-02-25 HR HRP20161165TT patent/HRP20161165T1/hr unknown
- 2013-02-25 EA EA201400960A patent/EA025692B1/ru not_active IP Right Cessation
- 2013-02-25 PL PL13715263T patent/PL2819655T3/pl unknown
- 2013-02-25 SG SG11201405316WA patent/SG11201405316WA/en unknown
- 2013-02-25 UA UAA201409664A patent/UA113301C2/uk unknown
- 2013-02-25 MX MX2014010237A patent/MX348222B/es active IP Right Grant
- 2013-02-27 AR ARP130100596A patent/AR090169A1/es unknown
- 2013-02-27 TW TW102106817A patent/TWI626042B/zh not_active IP Right Cessation
-
2014
- 2014-08-07 IL IL234009A patent/IL234009B/en active IP Right Grant
- 2014-08-12 ZA ZA2014/05910A patent/ZA201405910B/en unknown
- 2014-08-14 PH PH12014501837A patent/PH12014501837A1/en unknown
- 2014-08-19 CL CL2014002203A patent/CL2014002203A1/es unknown
-
2016
- 2016-10-12 SM SM201600363T patent/SMT201600363B/it unknown
- 2016-10-26 CY CY20161101079T patent/CY1118166T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6966584B2 (ja) | ドラベ症候群の処置における使用のためのフェンフルラミン | |
| TWI298020B (en) | Gabapentin analogues for sleep disorders | |
| ES2380060T3 (es) | Composiciones farmacéuticas de un esteroide neuroactivo y usos de las mismas | |
| US9682069B2 (en) | Methods of treating Dravet syndrome | |
| Kang et al. | Comparison of short‐versus long‐term ketogenic diet for intractable infantile spasms | |
| Wilder et al. | Gastrointestinal tolerance of divalproex sodium | |
| WO1999025329A1 (fr) | Utilisation de derives de benzhydryl sulfinyle pour traiter la somnolence d'origine medicamenteuse | |
| Xie et al. | In vitro and in vivo evaluations of PLGA microspheres containing nalmefene | |
| CA3177277A1 (en) | Methods of use of t-type calcium channel modulators | |
| Wu et al. | Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats | |
| HUE030737T2 (en) | Modafinil for use in the treatment of cocaine addicts | |
| US3954988A (en) | Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects | |
| CN1387434A (zh) | Nk1受体拮抗剂及gaba结构类似物的协同组合 | |
| CN103919774A (zh) | 去亚甲基小檗碱在制备降血脂药物中的应用 | |
| Ambulkar et al. | Neuroleptic malignant syndrome: a diagnostic challenge | |
| Waters | Treatment of advanced stage patients with Parkinson's disease | |
| US20140142113A1 (en) | Method of treating inflammatory diseases using adenosine 2b receptor antagonists | |
| Nicholson et al. | Development of oral extended release formulations of 6‐hydroxybuspirone | |
| Girardi et al. | Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients | |
| Fu-i et al. | Use of Risperidone Long-Acting Injection to Support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients | |
| Fabbrini et al. | Soluble and controlled-release preparations of levodopa: do we really need them? | |
| EP2891491A1 (en) | Use of (r)-phenylpiracetam for the treatment of sleep disorders | |
| Jabeen et al. | Studies on the effects of cyclodextrin polymer as a tableting aid on some selected analgesics | |
| WO2025188951A1 (en) | Fused amino pyrimidine compounds for treatment of seizure disorders | |
| WO2023247665A1 (en) | Solid dispersions of psilocybin |